Share on StockTwits

GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reaffirmed by analysts at Deutsche Bank in a research report issued to clients and investors on Thursday. They currently have a GBX 1,500 ($25.08) price target on the stock. Deutsche Bank’s price objective points to a potential upside of 5.82% from the stock’s previous close.

GlaxoSmithKline plc (LON:GSK) traded up 0.99% during mid-day trading on Thursday, hitting GBX 1431.50. The stock had a trading volume of 3,306,375 shares. GlaxoSmithKline plc has a 52-week low of GBX 1200.668 and a 52-week high of GBX 1706.00. The stock’s 50-day moving average is GBX 1478. and its 200-day moving average is GBX 1582.. The company’s market cap is £68.769 billion.

The company also recently announced a dividend, which is scheduled for Thursday, October 2nd. Investors of record on Wednesday, August 6th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.28%. The ex-dividend date of this dividend is Wednesday, August 6th.

A number of other firms have also recently commented on GSK. Analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday. They now have a GBX 1,385 ($23.15) price target on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Friday, August 15th. They now have a GBX 1,475 ($24.66) price target on the stock. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,634.81 ($27.33).

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.